Evaluation and Optimization of INR Goals in Patients With Mechanical Aortic Valves in a Pharmacist-Run Clinic: An Anticoagulation Stewardship Initiative [0.03%]
药师管理的心脏病诊所中机械瓣膜患者INR目标值的评估与优化：一项抗凝 stewardship 项目
Barbara Wang,Madison Hubert,Malgorzata Symons et al.
Barbara Wang et al.
Background: Patients with a mechanical aortic valve replacement (AVR) require lifelong anticoagulation with warfarin. International normalized ratio (INR) goals for mechanical AVRs can change throughout treatment as risk ...
Estimating GFR Using Creatinine, Cystatin C, or Both and the Impact on Predicted Vancomycin Half-Life [0.03%]
基于血清肌酐、胱抑素C或联合估算肾小球滤过率对预测万古霉素半衰期的影响
Amanda Dobson,Robert MacLaren,Shelby Pons et al.
Amanda Dobson et al.
Background: Glomerular filtration rate (GFR) is commonly estimated with equations using creatinine, cystatin C, or a combination of both. Drug dosages may differ depending on the which equation. ...
Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors [0.03%]
Fitusiran：一种新型抗凝血酶疗法用于甲型和乙型血友病患者（有或无抑制物）
Mohammad T Alashqar,Milap C Nahata
Mohammad T Alashqar
Objective: The objective of the study is to critically review the literature about clinical evidence on the efficacy and safety of fitusiran among patients with hemophilia A or B. ...
Gabapentinoids in Chronic Kidney Disease: A Closer Look at Respiratory Risk [0.03%]
慢性肾病患者的加巴喷丁类药物治疗：仔细评估呼吸系统风险
Lauren Harven,Renee Alexander Paxton,Christopher Giuliano
Lauren Harven
Background: In 2019, the Food and Drug Administration issued a warning regarding the risk of respiratory depression with gabapentin use, especially when combined with opioids or other central nervous system depressants. W...
Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review [0.03%]
.librikizumab-lbkz治疗特应性皮炎的药物评价
Danial Nasim,Brett Shaffer,Steven R Feldman
Danial Nasim
Background: Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the t...
Evaluation of the Use of Primary Prevention Aspirin in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant for Stroke Prevention [0.03%]
评估直接口服抗凝药治疗房颤患者的一级预防阿司匹林使用情况
Storee A Yzaguirre,Matthew R Rockhold,Thomas W Szymanski et al.
Storee A Yzaguirre et al.
Background: Current guidelines advise against use of aspirin for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with increased bleeding risk, including use of anticoagulation. However, li...
Creating Solutions to the Challenges in Managing Heparin Infusions: Exploring Use of Technology Including Artificial Intelligence and the Role of Anticoagulation Stewardship [0.03%]
应对肝素输注管理挑战的解决方案：包括人工智能技术的应用以及抗凝治疗质量管理的角色探讨
William E Dager
William E Dager
Adverse events and medication-related errors are common with anticoagulants. Heparin infusions are frequently associated with administration errors or challenges potentially leading to undesired events. Solving these challenges is multi-fac...
Rasburicase Real-World Usage for the Prevention and Treatment of Tumor Lysis Syndrome in Adults and Children [0.03%]
瑞舒卡肽在成人和儿童肿瘤溶解综合征预防和治疗中的真实世界用药状况
Sandra Labonté,Émilie Bergeron,Isabelle Laverdière et al.
Sandra Labonté et al.
Background: Rasburicase is used to prevent and treat tumor lysis syndrome (TLS) by breaking down uric acid. Administration methods vary, including fixed, weight-based (0.15-0.2 mg/kg), single and multiple doses. Our prima...
İrem Aşık Bal,İrfan Yavaşoğlu
İrem Aşık Bal
Utilization of FAERS Public Dashboard to Identify Letermovir-Associated Safety Signals [0.03%]
利用FAERS公共仪表板识别莱特莫韦相关安全性信号
Zhibin Xu,Lulin Wang,Xiaohua Wang et al.
Zhibin Xu et al.